The Clinical and Mechanism Study on the Effect of Yiqi Yangyin Decotion (YQYYD) on Prevention for Patients with Early Stage Lung Cancer
- Conditions
- Early Stage Lung Cancer
- Registration Number
- ITMCTR2000003734
- Lead Sponsor
- onghua Hospital, Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients with stage I lung cancer who met the diagnostic criteria of primary lung cancer and were confirmed by histopathology or cytology included adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma and large cell carcinoma;
(2) ground glass nodule (GGN) was found on CT scan, which indicated that it was adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) (mainly judged by size and density), with an average diameter of > 6 Mm, generally not exceeding 12mm, or CT scan revealed clear nodules of the same type before operation, mainly with ground glass nodules (solid nodules need more strict diagnosis and exclusion);
(3) syndrome differentiation of Qi and yin deficiency by TCM;
(4) 6 months or more after untreated or previous inhalation of budesonide;
(5) heart, liver, kidney and blood tests were all in normal range.
(6) Sign informed consent.
(1) Patients with other primary malignant tumors;
(2) Patients with serious heart, liver and kidney diseases and severe functional disorders;
(3) Pregnant or lactating women;
(4) Mental or cognitive disorders that affect the judgment of this study;
(5) Those who are participating in other drug trials;
(6) Those who are allergic to the drugs in this study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Size and density of GGO;
- Secondary Outcome Measures
Name Time Method quality of life (QOL);Cell free DNA (TP53, EGFR, PIK3CA);Tumor markers;immune function markers;